ArriVent BioPharma Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ null, 47.41, 171.68, 317.03, 481.79 ], "ebit_estimate": [ -197.12, -178.35, -81.3, 46.97, 195.3 ], "ebitda_estimate": [ -189.11, -156.79, -52.38, null, null ], "net_income_estimate": [ -187.77, -169.87, -78.15, 50.44, 201.33 ], "per_share_eps_estimate": [ -4.07, -3.56, -2.06, 0.56, 2.83 ], "eps_nri_estimate": [ -4.05, -3.44, -1.41, 1.06, 3.72 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null ], "pretax_income_estimate": [ -188.3, -169.87, -73.83, 57.5, 208.83 ], "operating_cash_flow_per_share_estimate": [ -7.35, -4.37, 0.13, 4.25, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ -72.72, -55.08, 13.96, null, null ], "gross_margin_estimate": [ null, null, null, null, null ], "operating_cash_flow_estimate": [ -331.25, -196.95, 5.86, 191.54, null ], "pettm_estimate": [ 0, 0, 0, 60.59, 11.89 ], "long_term_growth_rate_mean": 29.64, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": 20.97, "future_eps_nri_estimate_growth": 29.64, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": 21.67, "future_ebitda_estimate_growth": 31.95, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 21.07, "future_pretax_income_estimate_growth": 22.43, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ null, null, null, 9.7, 9.7, 12.6, 22.6 ], "ebit_estimate": [ -47.72, -51.16, -55.61, -51.48, -52.28, -48.02, -38.12 ], "ebitda_estimate": [ -46.69, -47.72, -48.32, null, null, null, null ], "net_income_estimate": [ -45.53, -49.3, -54.07, -48.78, -49.58, -45.45, -35.75 ], "per_share_eps_estimate": [ -0.99, -1.02, -1.11, -0.96, -0.98, -0.92, -0.77 ], "eps_nri_estimate": [ -0.99, -1.01, -1.08, -0.96, -0.98, -0.92, -0.77 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ -45.61, -49.66, -54.81, -48.78, -49.58, -45.45, -35.75 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ -59.92, -71.39, -86.84, null, null, null, null ], "gross_margin_estimate": [ null, null, null, null, null, null, null ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": 29.64, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": 20.97, "future_eps_nri_estimate_growth": 29.64, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": 21.67, "future_ebitda_estimate_growth": 31.95, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 21.07, "future_pretax_income_estimate_growth": 22.43, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }